| Intravascular stenting has become one of the most effective therapy methods for treatment of coronary artery angiemphraxis diseases. Bare metal stentscan cause in-stent restenosis. Drug eluting stents (DES) have dramatically reduced the incidence of in-stent restenosis and the incidence of adverse events. But, DES would lead hypersensitivity reactions, inflammatory reactions, vascular intimal hyperplasia and late stent thrombosis. The emergence of Endothelial Progenitor Cell (EPCs) capture technology represents the next generation stents approach to controlling stent thrombosis and restenosis.In this research, Hyaluronan and Chitosan electrostatic self-assembly multilayers coating endovascular stents loading with CD34 or CD133 antibody were first prepared. Observing the surface of basis coating by atomic mechanics microscope, there was uniformly dense island arrangement. The bioactive matrix coatings effectively improved hemocompatibility of the metal stent surface by platelet adhesion experiment by scanning electron microscopy. The feasibility of accelerate endothelialization was evaluated by scanning electron microscopy and immunofluorescence. The antibody stents can capture EPCs rapidly in fresh human peripheral blood in vitro. After implanting CD34 or CD133 coated stents in rabbit vessel, EPCs in the peripheral blood can be quickly and specificity captured by CD34 or CD133 monoclonal antibody on the stent surface, differentiated into vascular endothelial cells by fluorescence immunohistochemistry. 48 hours later, about 85% of stent surface was covered with monolayer vascular endothelial cells. CD34 or CD133 antibody stents would accelerate to repair injured vessel caused by stent expanding, which would be a more natural strategy to prevent restenosis and thrombosis. The glycosaminoglycan CD133 antibody nano-metal coating stent would be a novel way to prevent thrombogenesis and instent restenosis more safely. |
PDF Full Text Request